Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Controlled Release of Nanostructured Drug Systems (Volume II)
share announcement

Controlled Release of Nanostructured Drug Systems (Volume II)

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (20 November 2022) | Viewed by 16397

Special Issue Editors

Prof. Dr. Maria Luisa García

E-Mail Website
Guest Editor
Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain
Interests: drug delivery systems; nanoparticles; nanomedicines; nanobiomedicine; ocular drug delivery
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Elena Sánchez-López

E-Mail Website
Guest Editor
1. Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain
2. Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Barcelona, Spain
Interests: drug delivery systems; nanoparticles; biodegradable nanoparticles; neurodegenerative diseases; ocular drug delivery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Controlled-release formulations are aimed to modulate a drug pharmacokinetic profile by maintaining steady concentrations of the drug in the blood or target tissues. These nanostructured systems are able to improve drugs’ therapeutic efficacy and reduce their toxicity and adverse effects. In addition, nanocarriers have been shown to possess unique physical and chemical features and have been recently used in medicine for drug delivery and targeting.

This Special Issue on “Controlled Drug Release of Nanostructured Drug Systems” of Pharmaceutics addresses this multidisciplinary field and aims to discuss innovative advances in the design and applications of nanostructured systems for diagnosis, therapeutics, and cosmetics, among other relevant fields. Colleagues are invited to participate by proposing original and review papers that deal with new strategies and approaches for nanostructured systems applied in pharmaceutical and biomedical sciences, with a special focus on functionalized nanostructured systems.

Prof. Dr. Maria Luisa García
Prof. Dr. Elena Sánchez-López
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • controlled drug release
  • nanocarriers
  • drug delivery
  • nanomedicine
  • nanobiotechnology
  • nanoparticles
  • targeting strategies

Related Special Issue

Published Papers (7 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 5521 KiB  
Article
Conventional and PEGylated Liposomes as Vehicles of Copaifera sabulicola
by Ian M. R. Blanco, Raquel de Melo Barbosa, Julita M. P. Borges, Silvio A. B. Vieira de Melo, Ramon dos Santos El-Bachá, César Viseras, Patricia Severino, Elena Sanchez-Lopez, Eliana B. Souto and Elaine Cabral-Albuquerque
Pharmaceutics 2023, 15(2), 671; https://doi.org/10.3390/pharmaceutics15020671 - 16 Feb 2023
Cited by 2 | Viewed by 1581
Abstract
Traditional medicine uses resin oils extracted from plants of the genus Copaifera for several purposes. Resin oils are being studied to understand and profile their pharmacological properties. The aim of this work was to prepare and to characterize conventional and pegylated liposomes incorporating [...] Read more.
Traditional medicine uses resin oils extracted from plants of the genus Copaifera for several purposes. Resin oils are being studied to understand and profile their pharmacological properties. The aim of this work was to prepare and to characterize conventional and pegylated liposomes incorporating resin oils or the hexanic extract obtained from Copaifera sabulicola (copaiba) leaves. The cytotoxic effect of these products was also investigated. Conventional and stealth liposomes with copaiba extract showed similar average diameters (around 126 nm), encapsulation efficiencies greater than 75% and were stable for 90 days. A cytotoxicity test was performed on murine glioma cells and the developed liposomes presented antiproliferative action against these cancer cells at the average concentration of 30 μg/mL. Phytochemicals encapsulated in PEGylated liposomes induced greater reduction in the viability of tumor cells. In addition, bioassay-s measured the cytotoxicity of copaiba resin oil (Copaifera sabulicola) in liposomes (conventional and PEGylated), which was also checked against pheochromocytoma PC12 cells. Its safety was verified in normal rat astrocytes. The results indicate that liposomes encapsulating copaiba oil showed cytotoxic activity against the studied tumor strains in a dose-dependent fashion, demonstrating their potential applications as a chemotherapeutic bioactive formulation. Full article
(This article belongs to the Special Issue Controlled Release of Nanostructured Drug Systems (Volume II))
►▼ Show Figures

Figure 1

14 pages, 2042 KiB  
Article
Diclofenac Loaded Biodegradable Nanoparticles as Antitumoral and Antiangiogenic Therapy
by Gerard Esteruelas, Eliana B. Souto, Marta Espina, María Luisa García, Marta Świtalska, Joanna Wietrzyk, Anna Gliszczyńska and Elena Sánchez-López
Pharmaceutics 2023, 15(1), 102; https://doi.org/10.3390/pharmaceutics15010102 - 28 Dec 2022
Cited by 7 | Viewed by 1563
Abstract
Cancer is identified as one of the main causes of death worldwide, and an effective treatment that can reduce/eliminate serious adverse effects is still an unmet medical need. Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), has demonstrated promising antitumoral properties. However, the prolonged use [...] Read more.
Cancer is identified as one of the main causes of death worldwide, and an effective treatment that can reduce/eliminate serious adverse effects is still an unmet medical need. Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), has demonstrated promising antitumoral properties. However, the prolonged use of this NSAID poses several adverse effects. These can be overcome by the use of suitable delivery systems that are able to provide a controlled delivery of the payload. In this study, Diclofenac was incorporated into biodegradable polymeric nanoparticles based on PLGA and the formulation was optimized using a factorial design approach. A monodisperse nanoparticle population was obtained with a mean size of ca. 150 nm and negative surface charge. The release profile of diclofenac from the optimal formulation followed a prolonged release kinetics. Diclofenac nanoparticles demonstrated antitumoral and antiangiogenic properties without causing cytotoxicity to non-tumoral cells, and can be pointed out as a safe, promising and innovative nanoparticle-based formulation with potential antitumoral effects. Full article
(This article belongs to the Special Issue Controlled Release of Nanostructured Drug Systems (Volume II))
►▼ Show Figures

Figure 1

22 pages, 7150 KiB  
Article
Bio-Responsive Carriers for Controlled Delivery of Doxorubicin to Cancer Cells
by Gheorghe Fundueanu, Marieta Constantin, Mihaela Turtoi, Sanda-Maria Bucatariu, Bogdan Cosman, Maria Anghelache, Geanina Voicu and Manuela Calin
Pharmaceutics 2022, 14(4), 865; https://doi.org/10.3390/pharmaceutics14040865 - 15 Apr 2022
Cited by 8 | Viewed by 2011
Abstract
The cellular internalization of drug carriers occurs via different endocytic pathways that ultimately involve the endosomes and the lysosomes, organelles where the pH value drops to 6.0 and 5.0, respectively. We aimed to design and characterize pH/temperature-responsive carriers for the effective delivery of [...] Read more.
The cellular internalization of drug carriers occurs via different endocytic pathways that ultimately involve the endosomes and the lysosomes, organelles where the pH value drops to 6.0 and 5.0, respectively. We aimed to design and characterize pH/temperature-responsive carriers for the effective delivery of the anti-tumoral drug doxorubicin. To this purpose, poly(N-isopropylacrylamide-co-vinylimidazole) was synthesized as an attractive pH/temperature-sensitive copolymer. Microspheres made of this copolymer, loaded with doxorubicin (MS-DXR), disintegrate in monodisperse nanospheres (NS-DXR) under conditions similar to that found in the bloodstream (pH = 7.4, temperature of 36 °C) releasing a small amount of payload. However, in environments that simulate the endosomal and lysosomal conditions, nanospheres solubilize, releasing the entire amount of drug. We followed the NS-DXR internalization using two cancer cell lines, hepatic carcinoma HepG2 cells and lung adenocarcinoma A549 cells. The data showed that NS-DXR are internalized to a greater extent by HepG2 cells than A549 cells, and this correlated with increased cytotoxicity induced by NS-DXR in HepG2 cells compared with A549 cells. Moreover, NS-DXR particles do not cause hemolysis and erythrocytes aggregation. Administered in vivo, NS-DXR localized in the liver and kidneys of mice, and the loading of DXR into NS resulted in the reduced renal clearance of DXR. In conclusion, the newly developed poly(N-isopropylacrylamide-co-vinyl imidazole) particles are biocompatible and may be introduced as carriers for doxorubicin to hepatic tumors. Full article
(This article belongs to the Special Issue Controlled Release of Nanostructured Drug Systems (Volume II))
►▼ Show Figures

Figure 1

Review

Jump to: Research

26 pages, 1520 KiB  
Review
Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges
by Amanda Cano, Álvaro Muñoz-Morales, Elena Sánchez-López, Miren Ettcheto, Eliana B. Souto, Antonio Camins, Mercè Boada and Agustín Ruíz
Pharmaceutics 2023, 15(1), 298; https://doi.org/10.3390/pharmaceutics15010298 - 16 Jan 2023
Cited by 8 | Viewed by 3222
Abstract
Neurodegenerative diseases constitute a group of pathologies whose etiology remains unknown in many cases, and there are no treatments that stop the progression of such diseases. Moreover, the existence of the blood–brain barrier is an impediment to the penetration of exogenous molecules, including [...] Read more.
Neurodegenerative diseases constitute a group of pathologies whose etiology remains unknown in many cases, and there are no treatments that stop the progression of such diseases. Moreover, the existence of the blood–brain barrier is an impediment to the penetration of exogenous molecules, including those found in many drugs. Exosomes are extracellular vesicles secreted by a wide variety of cells, and their primary functions include intercellular communication, immune responses, human reproduction, and synaptic plasticity. Due to their natural origin and molecular similarities with most cell types, exosomes have emerged as promising therapeutic tools for numerous diseases. Specifically, neurodegenerative diseases have shown to be a potential target for this nanomedicine strategy due to the difficult access to the brain and the strategy’s pathophysiological complexity. In this regard, this review explores the most important biological-origin drug delivery systems, innovative isolation methods of exosomes, their physicochemical characterization, drug loading, cutting-edge functionalization strategies to target them within the brain, the latest research studies in neurodegenerative diseases, and the future challenges of exosomes as nanomedicine-based therapeutic tools. Full article
(This article belongs to the Special Issue Controlled Release of Nanostructured Drug Systems (Volume II))
►▼ Show Figures

Figure 1

33 pages, 2599 KiB  
Review
Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems
by Nicola Paccione, Mahdieh Rahmani, Emilia Barcia and Sofía Negro
Pharmaceutics 2023, 15(1), 13; https://doi.org/10.3390/pharmaceutics15010013 - 20 Dec 2022
Cited by 1 | Viewed by 2758
Abstract
Parkinson’s disease (PD) is a devastating neurodegenerative disease characterized by progressive destruction of dopaminergic tissue in the central nervous system (CNS). To date, there is no cure for the disease, with current pharmacological treatments aimed at controlling the symptoms. Therefore, there is an [...] Read more.
Parkinson’s disease (PD) is a devastating neurodegenerative disease characterized by progressive destruction of dopaminergic tissue in the central nervous system (CNS). To date, there is no cure for the disease, with current pharmacological treatments aimed at controlling the symptoms. Therefore, there is an unmet need for new treatments for PD. In addition to new therapeutic options, there exists the need for improved efficiency of the existing ones, as many agents have difficulties in crossing the blood–brain barrier (BBB) to achieve therapeutic levels in the CNS or exhibit inappropriate pharmacokinetic profiles, thereby limiting their clinical benefits. To overcome these limitations, an interesting approach is the use of drug delivery systems, such as polymeric microparticles (MPs) and nanoparticles (NPs) that allow for the controlled release of the active ingredients targeting to the desired site of action, increasing the bioavailability and efficacy of treatments, as well as reducing the number of administrations and adverse effects. Here we review the polymeric micro- and nano-systems under investigation as potential new therapies for PD. Full article
(This article belongs to the Special Issue Controlled Release of Nanostructured Drug Systems (Volume II))
►▼ Show Figures

Figure 1

20 pages, 1291 KiB  
Review
Nanoparticles in Endodontics Disinfection: State of the Art
by Xavier Roig-Soriano, Eliana B. Souto, Firas Elmsmari, Maria Luisa Garcia, Marta Espina, Fernando Duran-Sindreu, Elena Sánchez-López and Jose Antonio González Sánchez
Pharmaceutics 2022, 14(7), 1519; https://doi.org/10.3390/pharmaceutics14071519 - 21 Jul 2022
Cited by 8 | Viewed by 2585
Abstract
Endodontic-related diseases constitute the fourth most expensive pathologies in industrialized countries. Specifically, endodontics is the part of dentistry focused on treating disorders of the dental pulp and its consequences. In order to treat these problems, especially endodontic infections, dental barriers and complex root [...] Read more.
Endodontic-related diseases constitute the fourth most expensive pathologies in industrialized countries. Specifically, endodontics is the part of dentistry focused on treating disorders of the dental pulp and its consequences. In order to treat these problems, especially endodontic infections, dental barriers and complex root canal anatomy should be overcome. This constitutes an unmet medical need since the rate of successful disinfection with the currently marketed drugs is around 85%. Therefore, nanoparticles constitute a suitable alternative in order to deliver active compounds effectively to the target site, increasing their therapeutic efficacy. Therefore, in the present review, an overview of dental anatomy and the barriers that should be overcome for effective disinfection will be summarized. In addition, the versatility of nanoparticles for drug delivery and their specific uses in dentistry are comprehensively discussed. Finally, the latest findings, potential applications and state of the art nanoparticles with special emphasis on biodegradable nanoparticles used for endodontic disinfection are also reviewed. Full article
(This article belongs to the Special Issue Controlled Release of Nanostructured Drug Systems (Volume II))
►▼ Show Figures

Figure 1

22 pages, 6026 KiB  
Review
Stimuli-Responsive Gold Nanocages for Cancer Diagnosis and Treatment
by Chunming Li, Tengyue Zhao, Lixian Li, Xiaogang Hu, Chao Li, Wanyi Chen and Yurong Hu
Pharmaceutics 2022, 14(7), 1321; https://doi.org/10.3390/pharmaceutics14071321 - 22 Jun 2022
Cited by 4 | Viewed by 1954
Abstract
With advances in nanotechnology, various new drug delivery systems (DDSs) have emerged and played a key role in the diagnosis and treatment of cancers. Over the last two decades, gold nanocages (AuNCs) have been attracting considerable attention because of their outstanding properties. This [...] Read more.
With advances in nanotechnology, various new drug delivery systems (DDSs) have emerged and played a key role in the diagnosis and treatment of cancers. Over the last two decades, gold nanocages (AuNCs) have been attracting considerable attention because of their outstanding properties. This review summarizes current advancements in endogenous, exogenous, and dual/multi-stimuli responsive AuNCs in drug delivery. This review focuses on the properties, clinical translation potential, and limitations of stimuli-responsive AuNCs for cancer diagnosis and treatment. Full article
(This article belongs to the Special Issue Controlled Release of Nanostructured Drug Systems (Volume II))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-7
Back to TopTop